91 search results for: expert insights

expert video

What Could Remission Mean in AD?

1 min

Dermatology

Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how disease modification in AD can impact the course of the disease and its associated comorbidities.

expert video

Can early intervention modify the course of AD?

5 min

Dermatology

Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.

expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

5 min

Rhinology

Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission

expert video

ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

20 min

Pulmonology

In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Sharon Dell highlights the available clinical biologic efficacy data in pediatric severe asthma, suggesting the potential for achieving clinical remission when added to an asthma management plan.

expert video

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

60 min

Dermatology

This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

5 min

Dermatology

In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

4 min

Dermatology

In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.

expert video

KOL Video Interview – Dr. Eric Simpson

5 min

Dermatology

In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: PanamaChange country/region